Sella Takei
Hiroshi Kinoshita
Mitsuru Kumihashi1- 1Department of Forensic Medicine Faculty of Medicine, Kagawa University, Kagawa, Japan
- 2Bio Design Inc., Tokyo, Japan
We present a fatal case of pilsicainide poisoning. Quantitative toxicological analysis revealed that the concentrations of pilsicainide in femoral blood and urine samples were 17.5 μg/mL and 136.9 μg/mL, respectively. No morphological changes due to poisoning were observed. Based on the autopsy findings, results of the toxicological examination, and investigation by the authorities, we concluded that the cause of death was due to pilsicainide poisoning.
1 Introduction
Pilsicainide, a class IC anti-arrythmic agent according to the Vaughan Williams classification, is prescribed for the treatment of supraventricular and ventricular tachyarrhythmia (Plosker, 2010; Baselt, 2017a) and is available in Japan and Korea (Plosker, 2010). It is rapidly absorbed from the gastrointestinal tract following oral administration, the elimination half-life is 4.4–4.9 h following single oral administration, and the volume of distribution (Vd) is 1.48 L/kg (Plosker, 2010). Its major electrophysiological action is a selective sodium channel blockade without effects on potassium channels, calcium channels, or adrenal receptors, causing a decrease in intracardiac conduction velocity and negative inotropic effects (Plosker, 2010). Severe intoxication (Ozeki et al., 1999; Horita et al., 2004; Nakata et al., 2006; Oe et al., 2009; Imazu et al., 2017; Oshima et al., 2019; Asano et al., 2020) and fatalities (Hikiji et al., 2008; Fukasawa et al., 2018) have been reported. Acute poisoning from cardiovascular drugs is mostly due to β-adrenergic antagonists or calcium channel blockers, and poisoning from anti-arrhythmic agents is relatively rare (Vucinić et al., 2003; Gummin et al., 2018). Here, we report a fatal case of poisoning by pilsicainide.
A Japanese woman (78 years of age; height, 141 cm; and weight, 30 kg) was found dead in her house. She had been prescribed drugs (furosemide: 40 mg/day, pilsicainide: 150 mg/day, verapamil: 40 mg/day, and warfarin: 1 mg/day) for the treatment of arrhythmia and chronic cardiac failure. Her build was small for that of a Japanese, but she had no history of an eating disorder (BMI, 15.1). Her son saw her taking the drugs around 7 a.m. on the day of her death. Then, around 9:30 a.m., her husband noticed that she suffered cardiopulmonary arrest and called an ambulance. The ambulance arrived at 9:50 a.m.; however, as rigor mortis of the jaw joint was recognized, cardiopulmonary resuscitation was not attempted, and she was pronounced dead. The timeline of the present case is shown in Figure 1.
FIGURE 1. Timeline of the case.
Autopsy findings indicated no evidence of external injury. The heart weighed 260 g and contained 330 mL of blood with a coagulum and a chicken fat clot. Histological examination revealed moderate fibrosis of the myocardium. The brain weighed 991 g and was atrophic, without injuries. The left and right lungs weighed 153 g and 200 g, respectively. The stomach contained a very small amount of reddish brown mucus. Signs other than congestion were not noted in other organs. A drug screening test using an IVeX Screen ® M-1 (Biodesign Inc, Tokyo, Japan) panel resulted negative. Samples of postmortem blood (blood in the left and right heart chambers and femoral venous blood), urine, bile, cerebrospinal fluid, and stomach contents were collected for toxicological investigation.
Sample preparation for toxicological examination was as follows: D5-diazepam and D5-phenobarbital were added to 100 µL sample as an internal standard (IS) before adding 500 µL of acetonitrile. Stomach contents and bile and urine samples were also diluted 10 times with ultrapure water, and IS and acetonitrile were added, respectively, and extracted similar to the blood samples. Extraction was performed following vortex agitation, and the centrifuged supernatant of each extract was used for liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis.
Toxicological analysis using LC-MS/MS was performed as described previously (Kinoshita et al., 2017). Briefly, separations were carried out using ekspert™ ultraLC 100-XL (Eksigent Part of Sciex, Framingham, MA). An L-column2 ODS (1.5 mm × 150 mm, 5.0 µm particle size; Chemicals Evaluation and Research Institutes, Tokyo, Japan) was used with a mobile phase of solvent A (5% methanol containing 10 mM ammonium formate) and solvent B (95% methanol containing 10 mM ammonium formate) with a flow rate of 0.1 mL/min. A QTrap® 4500 tandem mass spectrometer (Sciex) was used. Pilsicainide was detected by the electrospray ionization-positive mode using selective reaction monitoring (SRM). Quantitation of ethanol was performed using headspace gas chromatography.
2 Results and discussion
Pilsicainide, verapamil, furosemide, warfarin, acetaminophen, ephedrine, and methylephedrine were identified in each sample through toxicological analysis. Figures 2A–C show the SRM chromatogram and mass spectrum of pilsicainide in the present case. Table 1 shows the concentrations in the postmortem samples, along with the currently established lethal, toxic, and therapeutic ranges (Schulz et al., 2020). No ethanol was detected in the postmortem samples.
FIGURE 2. SRM chromatogram of pilsicainide in blood samples (A), product ion spectrum of precursor ion m/z 273.15 at a retention time of 10.1 min (B), and mass spectrum obtained from the blood sample and the mass spectrum of pilsicainide (C).
TABLE 1. Concentrations of each drug in the post-mortem samples (µg/mL).
Heart-to-peripheral blood concentration ratios of pilsicainide were within a range of 1.52–1.65 in the present case. This suggested a smaller postmortem distribution than that of another class IC anti-arrhythmic agent, flecainide (O’Sullivan et al., 1995). This finding may be due to the small Vd of pilsicainide (1.48 L/kg (Plosker, 2010)) compared to that of flecainide (5.5 L/kg (Tjandra-Maga et al., 1986; Hilberg et al., 1999)).
Following oral administration, 75%–86% of the pilsicainide dose is excreted through urine in an unchanged form, and a small proportion (4.5%–6.5%) of the dose is metabolized to 2-hydroxymethyate by cytochrome P450 (CYP) 2D6 (Fujitani et al., 1997) and eliminated in urine (Fukumoto et al., 2005; Plosker, 2010). The therapeutic plasma concentration of pilsicainide following oral administration is 0.2–0.9 μg/mL (Baselt, 2017a; Schulz et al., 2020), with fatal levels in blood reported within the range of 7.8–14.9 μg/mL (Hikiji et al., 2008; Fukasawa et al., 2018) (Table 2). Pilsicainide concentrations in the present case were all within this fatal range and markedly above the therapeutic range.
TABLE 2. Pilsicainide concentration in the body fluids associated with fatal intoxications reported in the scientific literature (µg/mL).
Pilsicainide is recognized as a safe drug, but shows pro-arrhythmic effects in cases of intoxication. Serum pilsicainide levels have been reported to show a significant positive correlation with the electrocardiographic findings of PQ, QRS, and ST intervals and QTc prolongation (Horita et al., 2004; Koike et al., 2016). Pilsicainide induces tachyarrhythmias such as ventricular tachycardia, as a result of QTc and QRS prolongation (Horita et al., 2004; Kaneko et al., 2012), and bradyarrhythmias such as sinus pause and atrioventricular block (Toeda et al., 2000). As cases of sudden cardiac death have been reported for this drug (Nakatani et al., 2014), the pro-arrhythmic effects of pilsicainide were speculated to have contributed to this death.
The stomach contents showing high concentrations of pilsicainide, furosemide, and verapamil indicated that the patient had ingested pilsicainide along with other drugs. Since blood concentrations of verapamil were above the therapeutic range and those of furosemide were below the therapeutic range, the possibility of drug–drug interactions between verapamil and pilsicainide should be considered. Verapamil is known to inhibit the activity of CYP3A4 (Scheen, 2011), but a clinically relevant effect on pilsicainide metabolism by CYP2D6 would not be expected (Fujitani et al., 1997; Fukumoto et al., 2005). Although verapamil is known to inhibit P-glycoprotein (p-GP), this transporter’s contribution to the renal excretion of pilsicainide is negligible (Shiga et al., 2012). While there does not appear to be relevant pharmacokinetic drug–drug interactions due to CYP or p-GP inhibition, there is a potential pharmacodynamic drug–drug interaction between verapamil and pilsicainide. As verapamil itself induces pharmacological effects such as bradycardia, hypotension, and atrioventricular block (Baselt, 2017b), it compounds the risk of bradyarrhythmias when taken in combination with pilsicainide.
We also identified furosemide, warfarin, acetaminophen, ephedrine, and methylephedrine from the postmortem samples. Acetaminophen, ephedrine, and methylephedrine appeared to have been derived from over-the-counter cold remedies. As blood levels of those drugs were all below the therapeutic ranges, they were considered less likely to have contributed to this death.
Based on the autopsy findings, the results of the toxicological examinations, and the investigations by the authorities, we concluded that the cause of death was due to massive intake of pilsicainide, as its blood concentration was extremely high, with a possible contribution of verapamil to the lethal process.
3 Brief summary
Pilsicainide, a class IC anti-arrythmic agent, is prescribed for the treatment of supraventricular and ventricular tachyarrhythmias. Here, we report a fatal case of poisoning by pilsicainide. A high concentration of pilsicainide was detected in blood by liquid chromatography with tandem mass spectrometry. Although pilsicainide is recognized as a safe drug, it has pro-arrhythmic effects in case of an overdose.
Data availability statement
The original contributions presented in the study are included in the article; further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving human participants were reviewed and approved by the Ethics Committee of Kagawa University Faculty of Medicine.
Author contributions
Conceptualization: ST and HK; investigation: ST and HK; study design: ST and HK; data gathering: ST, HK, MK, MJ, HA, and SK; original draft preparation: ST and HK; review and editing: ST, HK, MK, MJ, HA, and SK. All authors have read and agreed to the published version of the manuscript.
Conflict of interest
Author HA was employed by the company Bio Design Inc.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Asano, M., Hayakawa, T., Kato, Y., Kagawa, K., Goto, S., Branch, J., et al. (2020). Pilsicainide intoxication with neuropsychiatric symptoms treated with continuous hemodiafiltration. Intern Med. 59, 2191–2195. doi:10.2169/internalmedicine.4676-20
Baselt, R. C. (2017). “Pilsicainide,” in Disposition of toxic drugs and chemicals in man. 11th ed. (Seal Beach, CA: Biomedical Publications), 1726–1727.
Baselt, R. C. (2017). “Verapamil,” in Disposition of toxic drugs and chemicals in man. 11th ed. (Seal Beach, CA: Biomedical Publications), 2234–2236.
Fujitani, T., Kanai, Y., Okumura, H., Maeda, M., Sugita, O., Hayashi, T., et al. (1997). Species difference in the liver metabolism of antiarrhythmic agent pilsicainide hydrochloride. Xenobio Metabol Dispos 12, S255.
Fukasawa, M., Ninomiya, K., Kawakami, Y., Fuke, C., and Miyazaki, T. (2018). Pilsicainide poisoning an autopsy case and review of literature. Am. J. Forensic Med. Pathol. 39, 357–359. doi:10.1097/PAF.0000000000000422
Fukumoto, K., Tanemura, M., Tsuchishita, Y., Kusumoto, M., Matsumoto, K., Kamakura, S., et al. (2005). Effect of protein binding of pilsicainide on the pharmacokinetics. Drug Metab. Pharmacokinet. 20, 183–186. doi:10.2133/dmpk.20.183
Gummin, D. D., Mowry, J. B., Spyker, D. A., Brooks, D. E., Beuhler, M. C., Rivers, L. J., et al. (2018). 2018 annual report of the American association of poison control centers' national poison Data system (NPDS): 36th annual report. Clin. Toxicol. 57, 1220–1413. doi:10.1080/15563650.2019.1677022
Hikiji, W., Kudo, K., Nishida, N., Ishida, T., Usumoto, Y., Tsuji, A., et al. (2008). Acute fatal poisoning with pilsicainide and atenolol. Int. J. Leg. Med. 122, 503–506. doi:10.1007/s00414-008-0269-8
Hilberg, T., Ripel, Å., Slørdal, L., Bjørneboe, A., Mørland, J., Ripel, A., et al. (1999). The extent of postmortem drug redistribution in a rat model. J. Forensic Sci. 44, 12023J–12062J. doi:10.1520/jfs12023j
Horita, Y., Kanaya, H., Uno, Y., Yamazaki, T., Kaku, B., Funada, A., et al. (2004). A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings. Jpn. Heart J. 45, 1049–1056. doi:10.1536/jhj.45.1049
Imazu, T., Ymamsaki, M., Noguchi, A., Matsuda, S., Funakoshi, S., and Maeda, Y. (2017). Two patients served from pilsicainide intoxication by responsive drug monitoring in the intensive care unit. J. Jpn. Soc. Hosp. Pharm. 53, 1156–1160.
Kaneko, Y., Nakajima, T., Kato, T., and Kurabayashi, M. (2012). Pilsicainide-induced polymorphic ventricular tachycardia. Intern Med. 51, 443–444. doi:10.2169/internalmedicine.51.6828
Kinoshita, H., Tanaka, N., Takakura, A., Kumihashi, M., Jamal, M., Ito, A., et al. (2017). Flunitrazepam in stomach contents may be a good indicator of its massive ingestion. Rom. J. Leg. Med. 25, 193–195. doi:10.4323/rjlm.2017.193
Koike, H., Fujino, T., Koike, M., Yao, S., Shinohara, M., Kitahara, K., et al. (2016). Assessment of drug-induced proarrhythmias due to pilsicainide in patients with atrial tachyarrhythmias. J. Arrhythm. 32, 468–473. doi:10.1016/j.joa.2016.03.004
Nakata, K., Moriwaki, R., Yamaguchi, A., Takenouchi, S., Mato, T., and Tsutsumi, H. (2006). Case in which magnesium sulfate effectively treated ventricular tachycardia due to overdose of pilsicainide hydrochloride. Chudoku Kenkyu 19, 49–53.
Nakatani, S., Taniike, M., Makino, N., Egami, Y., Shutta, R., Tanouchi, J., et al. (2014). A case of sudden cardiac death due to pilsicainide-induced Torsades de Pointes. Korean Circ. J. 44, 122–124. doi:10.4070/kcj.2014.44.2.122
Oe, K., Nagata, M., and Mori, K. (2009). Pilsicainide intoxication presenting as left ventricular dyssynchrony in a patient on hemodialysis. J. Cardiol. 53, 136–139. doi:10.1016/j.jjcc.2008.07.002
Oshima, K., Murata, M., Aoki, M., and Hagiwara, S. (2019). Ventricular tachycardia due to overdose of pilsicainide. J. Jpn. Soc. Intensive Care Med. 26, 191–192. doi:10.3918/jsicm.26_191
O’Sullivan, J. J., McCarthy, P. T., and Wren, C. (1995). Differences in amiodarone, digoxin, flecainide and sotalol concentrations between antemortem serum and femoral postmortem blood. Hum. Exp. Toxicol. 14, 605–608. doi:10.1177/096032719501400709
Ozeki, S., Utsunomiya, T., Matsuo, S., and Yano, H. (1999). Pilsicainide intoxication in a patient with dehydration. Jpn. Circ. J. 63, 219–222. doi:10.1253/jcj.63.219
Scheen, A. J. (2011). Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin. Drug Metab. Toxicol. 7, 1065–1082. doi:10.1517/17425255.2011.586337
Schulz, M., Schmoldt, A., Andresen-Streichert, H., and Iwersen-Bergmann, S. (2020). Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit. Care 24, 195. doi:10.1186/s13054-020-02915-5
Shiga, T., Hashiguchi, M., Tanaka, T., Morozumi, N., Irie, S., Mochizuki, M., et al. (2012). Lack of contribution of p-glycoprotein-mediated transport to renal excretion of pilsicainide in humans. Jpn. J. Clin. Pharmacol. Ther. 43, 157–164. doi:10.3999/jscpt.43.157
Tjandra-Maga, T. B., Verbesselt, R., Van Hecken, A., Mullie, A., and De Schepper, P. J. (1986). Flecainide: Single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. Br. J. Clin. Pharmacol. 22, 309–316. doi:10.1111/j.1365-2125.1986.tb02892.x
Toeda, T., Susa, R., Saigawa, T., Abe, T., Yamaguchi, Y., Fuse, K., et al. (2000). A case of sinus pause due to the proarrhythmia of pilsicainide. Jpn. Heart J. 41, 405–410. doi:10.1536/jhj.41.405
Keywords: pilsicainide, poisoning, pro-arrhythmia, anti-arrhythmic agent, autopsy
Citation: Takei S, Kinoshita H, Kumihashi M, Jamal M, Abe H and Kimura S (2023) Case report: An autopsy case of pilsicainide poisoning. Front. Pharmacol. 14:1090265. doi: 10.3389/fphar.2023.1090265
Received: 05 November 2022; Accepted: 10 January 2023;
Published: 26 January 2023.
Edited by:
Dirk Steinritz, Ludwig Maximilian University of Munich, GermanyReviewed by:
Tobias Zellner, Technical University of Munich, GermanyElias Bekka, Universitätsklinik für Allgemeine Innere Medizin Inselspital, Switzerland
Copyright © 2023 Takei, Kinoshita, Kumihashi, Jamal, Abe and Kimura. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hiroshi Kinoshita, a2lub3NoaXRhLmhpcm9zaGlAa2FnYXdhLXUuYWMuanA=